JAMA Clinical Evidence Synopsis Section Editor: Mary McGrae McDermott, MD, Contributing Editor. We encourage authors to submit papers for consideration as a JAMA Clinical Evidence Synopsis. Please contact Dr McDermott at firstname.lastname@example.org
Author Affiliations: Department of Vascular Surgery, James Cook University Hospital, Middlesbrough, England (Dr Wong); National Clinical Guideline Centre, Royal College of Physicians, London, England (Dr Chong); and Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne, England (Dr Stansby).
Clinical Question Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality?
Bottom Line In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.
Wong PF, Chong L, Stansby G. Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication. JAMA. 2013;309(9):926-927. doi:10.1001/jama.2013.1490